ClinConnect ClinConnect Logo
Search / Trial NCT05756257

Blood Pressure Variability and Ischemic Stroke Outcome

Launched by YALE UNIVERSITY · Feb 22, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in blood pressure (called blood pressure variability) affect patients who have had an acute ischemic stroke, which is a type of stroke caused by a blockage in the blood supply to the brain. The researchers want to find out if blood pressure variability is linked to how well patients recover, both in terms of physical abilities and mental function. They are also exploring the reasons why blood pressure changes might negatively impact recovery and are investigating possible treatments to help manage these blood pressure fluctuations after a stroke.

To be eligible for this study, participants need to be between 65 and 74 years old and have experienced an ischemic stroke within the last 24 hours, confirmed by brain imaging tests. They should also have a certain level of stroke severity at the time of enrollment. If someone joins the study, they can expect to undergo assessments to track their recovery and may receive new treatments aimed at stabilizing their blood pressure. It's important to note that individuals with certain pre-existing health conditions or those who are unable to participate in specific tests may not be eligible for this trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Ischemic stroke according to the American Heart Association (AHA) definition and either:
  • 1. CT or MRI showing ischemic stroke in the anterior circulation (frontal, parietal or superior temporal lobes), or
  • 2. Occlusion of the internal carotid, middle cerebral or anterior cerebral arteries on computed tomography angiography (CTA) or magnetic resonance angiography (MRA)
  • Onset of ischemic stroke within 48 hours and able to get baseline pMRI within 72 hours of arrival
  • 4) NIH Stroke Scale ≥ 4 at time of enrollment
  • Exclusion Criteria:
  • Pre-morbid mRS ≥3
  • Predicted hospital system admission \<72 hours
  • Pacemaker or other MRI contraindications per American College of Radiology guidelines

About Yale University

Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.

Locations

Boston, Massachusetts, United States

Chicago, Illinois, United States

New Haven, Connecticut, United States

Patients applied

0 patients applied

Trial Officials

Adam de Havenon, MD

Principal Investigator

Yale University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials